Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

Edwards Lifesciences Corporation today announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the SAPIEN 3 valve.

Thumbnail

May the heart be with you: Transplant hopeful receives good news from Star Wars' Chewbacca

Avid Star Wars fan Austin Eggleston, a 15-year-old heart transplant hopeful, finally received the news he was going to receive a new heart from Chewbacca, the big, furry character from a galaxy far, far away. 

Abbott's MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation

ABBOTT PARK, Ill., March 19, 2018 — Abbott today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan granted national reimbursement for the company's MitraClip therapy to treat people with mitral regurgitation, a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward into the heart.

Mardil Medical Announces First Human Implants of the VenTouch® Triad Targeted Ventricular Reshaping System

MINNEAPOLIS, March 14, 2018 — Mardil Medical, Inc., today announced the first human implants of its VenTouch® Triad device. Designed as a combination therapy to simultaneously treat the dilated ventricle and the resulting distorted valve in patients suffering from Type IIIb Functional Mitral Valve Regurgitation (FMR), VenTouch is a less-invasive treatment for a condition that can, if left untreated, accelerate and worsen heart failure.

Study to determine whether stem cell therapy can boost defective hearts

Researchers at the University of Maryland Medical Center are investigating whether a stem cell treatment can improve outcomes for children born with hypoplastic left heart syndrome, in which the left half of the heart is unable to pump blood.

FDA approves smallest valve for babies with congenital heart defects

The FDA has approved the smallest mechanical heart valve yet, Abbott’s 15-millimeter Masters HP valve, which can be used to treat babies and toddlers in need of mitral or aortic valve replacement.

First Longeveron Mesenchymal Stem Cell Treatment Administered to an Infant with Rare Heart Condition as Part of Groundbreaking Clinical Trial

MIAMI, Feb. 27, 2018 — Longeveron announced that its pioneering clinical trial to treat infants with Hypoplastic Left Heart Syndrome officially started with the first patient receiving the company's mesenchymal stem cell therapy in a procedure performed at the University of Maryland Medical Center in Baltimore.

Thumbnail

All together now? Exploring the pros & cons of CHD survivorship clinics

A small but growing number of survivorship clinics for congenital heart disease (CHD) patients are popping up in healthcare systems across the country, but some cardiologists wonder if the model is sustainable.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.